CFA
AST.WS

CT Financial Advisors’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

CT Financial Advisors’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$0 Hold
1
– – ﹤0.01% 662
2016
Q4 		$1 Hold
1
– – ﹤0.01% 645
2016
Q3 		$1 Sell
1
-3
-75% -$1 ﹤0.01% 642
2016
Q2 		$1 Buy
+4
New +$2 ﹤0.01% 645

Other funds holding AST.WS

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CT Financial Advisors's AST.WS Position: Q1 2017 in Review

CT Financial Advisors held its Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) position steady in Q1 2017 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #662.

CT Financial Advisors first reported a position in AST.WS in Q2 2016 and has held it in 4 quarters since. The position peaked at $1 in Q4 2016. 35 funds tracked by Wall St. Rank hold AST.WS as of Q1 2017.

  • CT Financial Advisors held 1 share of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) worth $0 as of Q1 2017.
  • CT Financial Advisors left its Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) share count unchanged in Q1 2017.
  • Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) made up ﹤0.01% of CT Financial Advisors's portfolio in Q1 2017, its #662 holding.
  • CT Financial Advisors first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and has held it in 4 quarters since.
  • CT Financial Advisors's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $1 in Q4 2016.
  • 35 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.